Close
Revogene® C. difficile

Improves satisfaction among patients and physicians by providing rapid, accurate, actionable results for the detection of Clostridium difficile infection (CDI)

Catalog Number: 132994

Support & Documents

Why Revogene C. difficile?

Revogene provides healthcare systems an opportunity to minimize the overall burden of C. difficile through improved care and efficiency by helping to reduce the risk of missing a true positive with the accuracy of molecular. Fast, actionable results enable physicians to make informed decisions about patient management and treatment resulting in reduced healthcare costs associated with isolation and antibiotics. Revogene is a flexible, reliable molecular platform that allows health systems to provide testing closer to the patient and advance the quality of care through simplified sample processing and efficient workflow.

  • sample_result_icon
    Efficient workflow - Sample to result in 3 easy steps
  • assay_flexibility_icon
    Flexible platform - Run multiple assays with different sample types on a single run
  • expansion_icon
    Platform for growth - Single analyte and multiplex testing capability
  • tech_icon2
    Total solution - Can be paired with Meridian immunoassays for a scalable testing solution

The system is very easy to work with, I was able to start and run an experiment after only 5 minutes of training!

Ingrid Op den Buijs

Senior technician molecular diagnostics
PAMM Laboratories
Veldhoven, Netherlands

Definitive answers, confidence in results

Contact Sales

Definitive answers, confidence in results

Contact Sales

FAQs

Colonization is more common than C. diff infection. The patient exhibits NO clinical symptoms (asymptomatic) but may test positive for the C.diff organism or its toxin gene. With infection, the patient exhibits clinical symptoms and tests positive for the C.diff organism and/or its toxin.

Use a stool toxin test as part of a multi-step algorithm (ie, glutamate dehydrogenase [GDH] plus toxin; GDH plus toxin, arbitrated by nucleic acid amplification test [NAAT]; or NAAT plus toxin) rather than a NAAT alone for all specimens received in the clinical laboratory when there are no pre-agreed institutional criteria for patient stool submission.

Use a NAAT alone or a multi-step algorithm for testing (ie, GDH plus toxin; GDH plus toxin, arbitrated by NAAT; or NAAT plus toxin) rather than a toxin test alone when there are pre-agreed institutional criteria for patient stool submission.

There is insufficient data to recommend the use of biologic markers as an adjunct to diagnosis.

Revogene C. difficile – 87493

Get in touch with us

Contact Us

Welcome to

Please select your country to continue

Continue